Acute Myeloid Leukemia: A Concise Review

Beyond the first glance: anthracyclines in AML

(2015) Hugo F. Fernandez   BLOOD

How I treat mixed-phenotype acute leukemia

(2015) O. Wolach et al.   BLOOD

A randomized comparison of daunorubicin 90 mg/m 2 vs 60 mg/m 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients

(2015) Alan K. Burnett et al.   BLOOD

DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia

(2015) A. R. Sehgal et al.   CLINICAL CANCER RESEARCH

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial

(2015) N. Boissel et al.   HAEMATOLOGICA

Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502

(2015) Steven M. Devine et al.   JOURNAL OF CLINICAL ONCOLOGY

AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients

(2015) Tamara Alpermann et al.   LEUKEMIA RESEARCH

Acute Myeloid Leukemia

(2015) Hartmut Döhner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia

(2015) Amir T. Fathi et al.   SEMINARS IN HEMATOLOGY

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial

(2015) N. Boissel et al.   HAEMATOLOGICA

Optimal dose and schedule of consolidation in AML: Is there a standard?

(2014) Charles A. Schiffer   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia

(2014) H. K. Lee et al.   BLOOD

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

(2014) D. Grimwade et al.   BLOOD

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

(2014) R. C. Lindsley et al.   BLOOD

Genetic alterations of the cohesin complex genes in myeloid malignancies

(2014) S. Thota et al.   BLOOD

Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations

(2014) J.-B. Micol et al.   BLOOD

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells

(2014) S. Gill et al.   BLOOD

Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia

(2014) Liran I. Shlush et al.   NATURE

FLT3 Inhibitors in AML: Are We There Yet?

(2014) Akshay Sudhindra et al.   Current Hematologic Malignancy Reports

Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia

(2014) H. D. Klepin   Hematology-American Society of Hematology Education Program

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

(2013) M. Pratcorona et al.   BLOOD

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

(2013) K. Kojima et al.   BLOOD

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)

(2013) V. I. Gaidzik et al.   BLOOD

The genetic basis of myelodysplasia and its clinical relevance

(2013) M. Cazzola et al.   BLOOD

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

(2013) F. Ravandi et al.   BLOOD

Antibody therapy for acute myeloid leukaemia

(2013) Robin E. Gasiorowski et al.   BRITISH JOURNAL OF HAEMATOLOGY

Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial

(2013) Hubert Serve et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial

(2013) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of different genetic subtypes of CEBPA mutated AML

(2013) A Fasan et al.   LEUKEMIA

Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease

(2013) A Kohlmann et al.   LEUKEMIA

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

(2013) Francesco Lo-Coco et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia

(2012) A. Quintas-Cardama et al.   BLOOD

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

(2012) P. Ranganathan et al.   BLOOD

Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

(2012) Krzysztof Mrózek et al.   JOURNAL OF CLINICAL ONCOLOGY

Age-Related Prognostic Impact of Different Types ofDNMT3AMutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia

(2012) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

RUNX1Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures

(2012) Jason H. Mendler et al.   JOURNAL OF CLINICAL ONCOLOGY

TET2 Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group

(2012) Verena I. Gaidzik et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

How to manage acute promyelocytic leukemia

(2012) J-Q Mi et al.   LEUKEMIA

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells

(2012) J Etchin et al.   LEUKEMIA

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

(2012) Catherine C. Smith et al.   NATURE

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

(2012) Li Ding et al.   NATURE

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

(2011) K. H. Metzeler et al.   BLOOD

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

(2011) M. Levis et al.   BLOOD

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics

(2011) W.-C. Chou et al.   BLOOD

Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR

(2011) U Popat et al.   BONE MARROW TRANSPLANTATION

Azacitidine for the treatment of patients with acute myeloid leukemia

(2011) Luca Maurillo et al.   CANCER

Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications

(2011) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

TET2Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2011) Klaus H. Metzeler et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience

(2010) B. C. Medeiros et al.   BLOOD

IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2010) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication

(2010) Peter Paschka et al.   JOURNAL OF CLINICAL ONCOLOGY

DNMT3AMutations in Acute Myeloid Leukemia

(2010) Timothy J. Ley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

(2010) W. Blum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome

(2009) S. Kayser et al.   BLOOD

The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model

(2009) K. Cheng et al.   BLOOD

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations

(2009) J.-L. Tang et al.   BLOOD

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

(2009) B. J. Wouters et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Anthracycline Dose Intensification in Acute Myeloid Leukemia

(2009) Hugo F. Fernandez et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

(2009) Bob Löwenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

(2008) K. W. Pratz et al.   BLOOD

CRM1-Mediated Nuclear Export of Proteins and Drug Resistance in Cancer

(2008) Joel Turner et al.   CURRENT MEDICINAL CHEMISTRY

Dysregulation of the C/EBPα Differentiation Pathway in Human Cancer

(2008) Steffen Koschmieder et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype

(2008) C Haferlach et al.   LEUKEMIA

Targeting FLT3 for the Treatment of Leukemia

(2008) Donald Small   SEMINARS IN HEMATOLOGY

Prognostic Implications of Gene Mutations in Acute Myeloid Leukemia With Normal Cytogenetics

(2008) Verena Gaidzik et al.   SEMINARS IN ONCOLOGY